Emsam Approved - Bristol-Myers Squibb Company/Somerset Pharmaceuticals, Inc. - Treatment for Major Depressive Disorder
Emsam is a transdermal patch containing the monoamine oxidase inhibitor selegiline. Emsam is indicated for the treatment of major depressive disorder (MDD) in adults.Posted: February 2006
Related Articles:
- Somerset Files Response to Emsam Action Letter - June 16, 2005
- Mylan Laboratories and Watson Pharmaceuticals Announce Receipt of "Approvable" Letter for Emsam - February 2, 2004
Emsam (selegiline) FDA Approval History
